{
  "timestamp": "2026-01-07T17:07:32.683377",
  "total_queries": 86,
  "source_breakdown": {
    "dosing_guidance": 40,
    "synthetic_lethality": 40,
    "hypothesis_validator": 6
  },
  "queries": [
    {
      "query_id": "DG_001",
      "question": "How does capecitabine interact with DPYD c.2846A>T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "LIT-DPYD-001",
        "pmid": "41133273",
        "drug": "capecitabine",
        "gene": "DPYD",
        "variant": "c.2846A>T",
        "disease": "cancer",
        "toxicity_occurred": true,
        "toxicity_confidence": "high"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "c.2846A>T"
        }
      }
    },
    {
      "query_id": "DG_002",
      "question": "How does capecitabine interact with DPYD c.2846A>T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "LIT-DPYD-002",
        "pmid": "39376610",
        "drug": "capecitabine",
        "gene": "DPYD",
        "variant": "c.2846A>T",
        "disease": "cancer",
        "toxicity_occurred": true,
        "toxicity_confidence": "high"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "c.2846A>T"
        }
      }
    },
    {
      "query_id": "DG_003",
      "question": "How does 5-fluorouracil interact with DPYD in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "LIT-DPYD-003",
        "pmid": "38528593",
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "",
        "disease": "cancer",
        "toxicity_occurred": true,
        "toxicity_confidence": "high"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "WILDTYPE"
        }
      }
    },
    {
      "query_id": "DG_004",
      "question": "How does 5-fluorouracil interact with DPYD in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "LIT-DPYD-004",
        "pmid": "36160401",
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "WILDTYPE"
        }
      }
    },
    {
      "query_id": "DG_005",
      "question": "How does 5-fluorouracil interact with DPYD in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "LIT-DPYD-005",
        "pmid": "31486738",
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "WILDTYPE"
        }
      }
    },
    {
      "query_id": "DG_006",
      "question": "How does 5-fluorouracil interact with DPYD in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "LIT-DPYD-006",
        "pmid": "31382864",
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "WILDTYPE"
        }
      }
    },
    {
      "query_id": "DG_007",
      "question": "How does 5-fluorouracil interact with DPYD in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "LIT-DPYD-007",
        "pmid": "31149530",
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "",
        "disease": "cancer",
        "toxicity_occurred": true,
        "toxicity_confidence": "moderate"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "WILDTYPE"
        }
      }
    },
    {
      "query_id": "DG_008",
      "question": "How does capecitabine interact with DPYD c.1903A>G in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "LIT-DPYD-008",
        "pmid": "30915274",
        "drug": "capecitabine",
        "gene": "DPYD",
        "variant": "c.1903A>G",
        "disease": "cancer",
        "toxicity_occurred": true,
        "toxicity_confidence": "moderate"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "c.1903A>G"
        }
      }
    },
    {
      "query_id": "DG_009",
      "question": "How does 5-fluorouracil interact with DPYD in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "LIT-DPYD-009",
        "pmid": "28929491",
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "WILDTYPE"
        }
      }
    },
    {
      "query_id": "DG_010",
      "question": "How does mercaptopurine interact with TPMT *3A in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "LIT-TPMT-001",
        "pmid": "31464791",
        "drug": "mercaptopurine",
        "gene": "TPMT",
        "variant": "*3A",
        "disease": "cancer",
        "toxicity_occurred": true,
        "toxicity_confidence": "moderate"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "TPMT": "*3A"
        }
      }
    },
    {
      "query_id": "DG_011",
      "question": "How does 5-fluorouracil interact with DPYD A348T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "CBIO-coad_cptac_gdc-11CO036",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "A348T",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "A348T"
        }
      }
    },
    {
      "query_id": "DG_012",
      "question": "How does 5-fluorouracil interact with DPYD chr6:g.18139713G>T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-001",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr6:g.18139713G>T",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr6:g.18139713G>T"
        }
      }
    },
    {
      "query_id": "DG_013",
      "question": "How does 5-fluorouracil interact with DPYD chr6:g.18130698delA in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-002",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr6:g.18130698delA",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr6:g.18130698delA"
        }
      }
    },
    {
      "query_id": "DG_014",
      "question": "How does 5-fluorouracil interact with DPYD chr6:g.18149023G>A in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-003",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr6:g.18149023G>A",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr6:g.18149023G>A"
        }
      }
    },
    {
      "query_id": "DG_015",
      "question": "How does 5-fluorouracil interact with DPYD chr6:g.18130729C>T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-004",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr6:g.18130729C>T",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr6:g.18130729C>T"
        }
      }
    },
    {
      "query_id": "DG_016",
      "question": "How does 5-fluorouracil interact with DPYD chr6:g.18133864G>A in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-005",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr6:g.18133864G>A",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr6:g.18133864G>A"
        }
      }
    },
    {
      "query_id": "DG_017",
      "question": "How does 5-fluorouracil interact with DPYD chr6:g.18143662delA in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-006",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr6:g.18143662delA",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr6:g.18143662delA"
        }
      }
    },
    {
      "query_id": "DG_018",
      "question": "How does 5-fluorouracil interact with DPYD chr6:g.18143717C>A in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-007",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr6:g.18143717C>A",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr6:g.18143717C>A"
        }
      }
    },
    {
      "query_id": "DG_019",
      "question": "How does 5-fluorouracil interact with DPYD chr6:g.18130763G>A in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-008",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr6:g.18130763G>A",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr6:g.18130763G>A"
        }
      }
    },
    {
      "query_id": "DG_020",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97679174G>A in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-009",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97679174G>A",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97679174G>A"
        }
      }
    },
    {
      "query_id": "DG_021",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97828158C>A in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-010",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97828158C>A",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97828158C>A"
        }
      }
    },
    {
      "query_id": "DG_022",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97573967C>A in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-011",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97573967C>A",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97573967C>A"
        }
      }
    },
    {
      "query_id": "DG_023",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97721603A>G in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-012",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97721603A>G",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97721603A>G"
        }
      }
    },
    {
      "query_id": "DG_024",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97079145G>T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-013",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97079145G>T",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97079145G>T"
        }
      }
    },
    {
      "query_id": "DG_025",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97306282G>A in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-014",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97306282G>A",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97306282G>A"
        }
      }
    },
    {
      "query_id": "DG_026",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97593336A>G in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-015",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97593336A>G",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97593336A>G"
        }
      }
    },
    {
      "query_id": "DG_027",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97306235delA in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-016",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97306235delA",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97306235delA"
        }
      }
    },
    {
      "query_id": "DG_028",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97573918C>T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-017",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97573918C>T",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97573918C>T"
        }
      }
    },
    {
      "query_id": "DG_029",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97079073C>T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-018",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97079073C>T",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97079073C>T"
        }
      }
    },
    {
      "query_id": "DG_030",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97883365C>T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-019",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97883365C>T",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97883365C>T"
        }
      }
    },
    {
      "query_id": "DG_031",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97679126T>G in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-020",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97679126T>G",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97679126T>G"
        }
      }
    },
    {
      "query_id": "DG_032",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97082458T>C in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-021",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97082458T>C",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97082458T>C"
        }
      }
    },
    {
      "query_id": "DG_033",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97721543A>G in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-022",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97721543A>G",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97721543A>G"
        }
      }
    },
    {
      "query_id": "DG_034",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97699457G>A in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-023",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97699457G>A",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97699457G>A"
        }
      }
    },
    {
      "query_id": "DG_035",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97515906T>G in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-024",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97515906T>G",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97515906T>G"
        }
      }
    },
    {
      "query_id": "DG_036",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97234900A>G in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-025",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97234900A>G",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97234900A>G"
        }
      }
    },
    {
      "query_id": "DG_037",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97721569A>C in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-026",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97721569A>C",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97721569A>C"
        }
      }
    },
    {
      "query_id": "DG_038",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97549703G>T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-027",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97549703G>T",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97549703G>T"
        }
      }
    },
    {
      "query_id": "DG_039",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97595138G>T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-028",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97595138G>T",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97595138G>T"
        }
      }
    },
    {
      "query_id": "DG_040",
      "question": "How does 5-fluorouracil interact with DPYD chr1:g.97306195C>T in cancer?",
      "source": "dosing_guidance",
      "source_data": {
        "case_id": "GDC-TCGA-COAD-029",
        "pmid": null,
        "drug": "5-fluorouracil",
        "gene": "DPYD",
        "variant": "chr1:g.97306195C>T",
        "disease": "cancer",
        "toxicity_occurred": false,
        "toxicity_confidence": "inferred_from_lack_of_evidence"
      },
      "context": {
        "disease": "cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "DPYD": "chr1:g.97306195C>T"
        }
      }
    },
    {
      "query_id": "SL_001",
      "question": "What mechanisms does Olaparib target in ovarian cancer with p.C61G?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_001",
        "drug": "Olaparib",
        "gene": "BRCA1",
        "mutation": "p.C61G",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA1+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA1": 0.44405918068595746
          },
          "clinical_evidence": {
            "pmid": "25366685",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA1",
            "hgvs_p": "p.C61G",
            "chrom": "17",
            "pos": 43070943,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA1": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_002",
      "question": "What mechanisms does Olaparib target in breast cancer with p.C61G?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_002",
        "drug": "Olaparib",
        "gene": "BRCA1",
        "mutation": "p.C61G",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA1+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA1": 0.5136549385283461
          },
          "clinical_evidence": {
            "pmid": "28569902",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA1",
            "hgvs_p": "p.C61G",
            "chrom": "17",
            "pos": 43070943,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA1": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_003",
      "question": "What mechanisms does Olaparib target in prostate cancer with p.K3326*?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_003",
        "drug": "Olaparib",
        "gene": "BRCA2",
        "mutation": "p.K3326*",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA2+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA2": 0.5785124303033135
          },
          "clinical_evidence": {
            "pmid": "25366685",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA2",
            "hgvs_p": "p.K3326*",
            "chrom": "13",
            "pos": 32936750,
            "ref": "?",
            "alt": "?",
            "consequence": "stop_gained"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA2": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_004",
      "question": "What mechanisms does Olaparib target in ovarian cancer with p.K3326*?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_004",
        "drug": "Olaparib",
        "gene": "BRCA2",
        "mutation": "p.K3326*",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA2+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA2": 0.49663622684497655
          },
          "clinical_evidence": {
            "pmid": "30345854",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA2",
            "hgvs_p": "p.K3326*",
            "chrom": "13",
            "pos": 32936750,
            "ref": "?",
            "alt": "?",
            "consequence": "stop_gained"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA2": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_005",
      "question": "What mechanisms does Olaparib target in breast cancer with p.R346fs?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_005",
        "drug": "Olaparib",
        "gene": "MBD4",
        "mutation": "p.R346fs",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "MBD4+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "BER"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "MBD4": 0.12484960719544597
          },
          "clinical_evidence": {
            "pmid": "30111527",
            "evidence_level": "Preclinical"
          }
        },
        "mutations": [
          {
            "gene": "MBD4",
            "hgvs_p": "p.R346fs",
            "chrom": "3",
            "pos": 129430488,
            "ref": "?",
            "alt": "?",
            "consequence": "frameshift_variant"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "MBD4": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_006",
      "question": "What mechanisms does Ceralasertib target in prostate cancer with p.R175H?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_006",
        "drug": "Ceralasertib",
        "gene": "TP53",
        "mutation": "p.R175H",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "TP53+ATR"
          ],
          "effective_drugs": [
            "Ceralasertib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "ATR/CHK1"
          ],
          "depmap_essentiality": {
            "TP53": 0.0
          },
          "clinical_evidence": {
            "pmid": "33115855",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "TP53",
            "hgvs_p": "p.R175H",
            "chrom": "17",
            "pos": 7577120,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "TP53": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_007",
      "question": "What mechanisms does Adavosertib target in ovarian cancer with p.R175H?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_007",
        "drug": "Adavosertib",
        "gene": "TP53",
        "mutation": "p.R175H",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "TP53+WEE1"
          ],
          "effective_drugs": [
            "Adavosertib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "ATR/CHK1"
          ],
          "depmap_essentiality": {
            "TP53": 0.0
          },
          "clinical_evidence": {
            "pmid": "32592347",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "TP53",
            "hgvs_p": "p.R175H",
            "chrom": "17",
            "pos": 7577120,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "TP53": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_008",
      "question": "What mechanisms does Olaparib target in breast cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_008",
        "drug": "Olaparib",
        "gene": "ATM",
        "mutation": "p.?",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "ATM+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "ATM": 0.03199998891214332
          },
          "clinical_evidence": {
            "pmid": "29880560",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "ATM",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "ATM": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_009",
      "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_009",
        "drug": "Olaparib",
        "gene": "PALB2",
        "mutation": "p.?",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "PALB2+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "PALB2": 0.4837245019947514
          },
          "clinical_evidence": {
            "pmid": "32592347",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "PALB2",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "PALB2": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_010",
      "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_010",
        "drug": "Olaparib",
        "gene": "RAD51C",
        "mutation": "p.?",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "RAD51C+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "RAD51C": 0.7061312400750432
          },
          "clinical_evidence": {
            "pmid": "30345854",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "RAD51C",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "RAD51C": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_011",
      "question": "What mechanisms does Olaparib target in breast cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_011",
        "drug": "Olaparib",
        "gene": "RAD51D",
        "mutation": "p.?",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "RAD51D+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "RAD51D": 0.7293221853155034
          },
          "clinical_evidence": {
            "pmid": "30345854",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "RAD51D",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "RAD51D": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_012",
      "question": "What mechanisms does Ceralasertib target in prostate cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_012",
        "drug": "Ceralasertib",
        "gene": "ARID1A",
        "mutation": "p.?",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "ARID1A+ATR"
          ],
          "effective_drugs": [
            "Ceralasertib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "ATR/CHK1"
          ],
          "depmap_essentiality": {
            "ARID1A": 0.375561921664032
          },
          "clinical_evidence": {
            "pmid": "30510156",
            "evidence_level": "Preclinical"
          }
        },
        "mutations": [
          {
            "gene": "ARID1A",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "ARID1A": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_013",
      "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_013",
        "drug": "Olaparib",
        "gene": "CDK12",
        "mutation": "p.?",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "CDK12+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "CDK12": 0.4085607197529356
          },
          "clinical_evidence": {
            "pmid": "31320749",
            "evidence_level": "Preclinical"
          }
        },
        "mutations": [
          {
            "gene": "CDK12",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "CDK12": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_014",
      "question": "What mechanisms does Olaparib target in breast cancer with p.C61G?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_014",
        "drug": "Olaparib",
        "gene": "BRCA1",
        "mutation": "p.C61G",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA1+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA1": 0.5136549385283461
          },
          "clinical_evidence": {
            "pmid": "25366685",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA1",
            "hgvs_p": "p.C61G",
            "chrom": "17",
            "pos": 43070943,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA1": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_015",
      "question": "What mechanisms does Olaparib target in prostate cancer with p.C61G?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_015",
        "drug": "Olaparib",
        "gene": "BRCA1",
        "mutation": "p.C61G",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA1+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA1": 0.31676202596271663
          },
          "clinical_evidence": {
            "pmid": "28569902",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA1",
            "hgvs_p": "p.C61G",
            "chrom": "17",
            "pos": 43070943,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA1": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_016",
      "question": "What mechanisms does Olaparib target in ovarian cancer with p.K3326*?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_016",
        "drug": "Olaparib",
        "gene": "BRCA2",
        "mutation": "p.K3326*",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA2+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA2": 0.49663622684497655
          },
          "clinical_evidence": {
            "pmid": "25366685",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA2",
            "hgvs_p": "p.K3326*",
            "chrom": "13",
            "pos": 32936750,
            "ref": "?",
            "alt": "?",
            "consequence": "stop_gained"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA2": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_017",
      "question": "What mechanisms does Olaparib target in breast cancer with p.K3326*?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_017",
        "drug": "Olaparib",
        "gene": "BRCA2",
        "mutation": "p.K3326*",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA2+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA2": 0.5194046762092465
          },
          "clinical_evidence": {
            "pmid": "30345854",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA2",
            "hgvs_p": "p.K3326*",
            "chrom": "13",
            "pos": 32936750,
            "ref": "?",
            "alt": "?",
            "consequence": "stop_gained"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA2": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_018",
      "question": "What mechanisms does Olaparib target in prostate cancer with p.R346fs?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_018",
        "drug": "Olaparib",
        "gene": "MBD4",
        "mutation": "p.R346fs",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "MBD4+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "BER"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "MBD4": 0.1133053958772785
          },
          "clinical_evidence": {
            "pmid": "30111527",
            "evidence_level": "Preclinical"
          }
        },
        "mutations": [
          {
            "gene": "MBD4",
            "hgvs_p": "p.R346fs",
            "chrom": "3",
            "pos": 129430488,
            "ref": "?",
            "alt": "?",
            "consequence": "frameshift_variant"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "MBD4": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_019",
      "question": "What mechanisms does Ceralasertib target in ovarian cancer with p.R175H?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_019",
        "drug": "Ceralasertib",
        "gene": "TP53",
        "mutation": "p.R175H",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "TP53+ATR"
          ],
          "effective_drugs": [
            "Ceralasertib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "ATR/CHK1"
          ],
          "depmap_essentiality": {
            "TP53": 0.0
          },
          "clinical_evidence": {
            "pmid": "33115855",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "TP53",
            "hgvs_p": "p.R175H",
            "chrom": "17",
            "pos": 7577120,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "TP53": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_020",
      "question": "What mechanisms does Adavosertib target in breast cancer with p.R175H?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_020",
        "drug": "Adavosertib",
        "gene": "TP53",
        "mutation": "p.R175H",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "TP53+WEE1"
          ],
          "effective_drugs": [
            "Adavosertib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "ATR/CHK1"
          ],
          "depmap_essentiality": {
            "TP53": 0.0
          },
          "clinical_evidence": {
            "pmid": "32592347",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "TP53",
            "hgvs_p": "p.R175H",
            "chrom": "17",
            "pos": 7577120,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "TP53": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_021",
      "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_021",
        "drug": "Olaparib",
        "gene": "ATM",
        "mutation": "p.?",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "ATM+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "ATM": 0.05858248553710228
          },
          "clinical_evidence": {
            "pmid": "29880560",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "ATM",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "ATM": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_022",
      "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_022",
        "drug": "Olaparib",
        "gene": "PALB2",
        "mutation": "p.?",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "PALB2+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "PALB2": 0.33189795944643924
          },
          "clinical_evidence": {
            "pmid": "32592347",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "PALB2",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "PALB2": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_023",
      "question": "What mechanisms does Olaparib target in breast cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_023",
        "drug": "Olaparib",
        "gene": "RAD51C",
        "mutation": "p.?",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "RAD51C+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "RAD51C": 0.7042390620749244
          },
          "clinical_evidence": {
            "pmid": "30345854",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "RAD51C",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "RAD51C": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_024",
      "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_024",
        "drug": "Olaparib",
        "gene": "RAD51D",
        "mutation": "p.?",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "RAD51D+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "RAD51D": 0.5788916280524823
          },
          "clinical_evidence": {
            "pmid": "30345854",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "RAD51D",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "RAD51D": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_025",
      "question": "What mechanisms does Ceralasertib target in ovarian cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_025",
        "drug": "Ceralasertib",
        "gene": "ARID1A",
        "mutation": "p.?",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "ARID1A+ATR"
          ],
          "effective_drugs": [
            "Ceralasertib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "ATR/CHK1"
          ],
          "depmap_essentiality": {
            "ARID1A": 0.2596675073474911
          },
          "clinical_evidence": {
            "pmid": "30510156",
            "evidence_level": "Preclinical"
          }
        },
        "mutations": [
          {
            "gene": "ARID1A",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "ARID1A": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_026",
      "question": "What mechanisms does Olaparib target in breast cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_026",
        "drug": "Olaparib",
        "gene": "CDK12",
        "mutation": "p.?",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "CDK12+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "CDK12": 0.48274278092286904
          },
          "clinical_evidence": {
            "pmid": "31320749",
            "evidence_level": "Preclinical"
          }
        },
        "mutations": [
          {
            "gene": "CDK12",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "CDK12": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_027",
      "question": "What mechanisms does Olaparib target in prostate cancer with p.C61G?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_027",
        "drug": "Olaparib",
        "gene": "BRCA1",
        "mutation": "p.C61G",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA1+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA1": 0.31676202596271663
          },
          "clinical_evidence": {
            "pmid": "25366685",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA1",
            "hgvs_p": "p.C61G",
            "chrom": "17",
            "pos": 43070943,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA1": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_028",
      "question": "What mechanisms does Olaparib target in ovarian cancer with p.C61G?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_028",
        "drug": "Olaparib",
        "gene": "BRCA1",
        "mutation": "p.C61G",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA1+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA1": 0.44405918068595746
          },
          "clinical_evidence": {
            "pmid": "28569902",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA1",
            "hgvs_p": "p.C61G",
            "chrom": "17",
            "pos": 43070943,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA1": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_029",
      "question": "What mechanisms does Olaparib target in breast cancer with p.K3326*?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_029",
        "drug": "Olaparib",
        "gene": "BRCA2",
        "mutation": "p.K3326*",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA2+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA2": 0.5194046762092465
          },
          "clinical_evidence": {
            "pmid": "25366685",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA2",
            "hgvs_p": "p.K3326*",
            "chrom": "13",
            "pos": 32936750,
            "ref": "?",
            "alt": "?",
            "consequence": "stop_gained"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA2": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_030",
      "question": "What mechanisms does Olaparib target in prostate cancer with p.K3326*?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_030",
        "drug": "Olaparib",
        "gene": "BRCA2",
        "mutation": "p.K3326*",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA2+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA2": 0.5785124303033135
          },
          "clinical_evidence": {
            "pmid": "30345854",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA2",
            "hgvs_p": "p.K3326*",
            "chrom": "13",
            "pos": 32936750,
            "ref": "?",
            "alt": "?",
            "consequence": "stop_gained"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA2": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_031",
      "question": "What mechanisms does Olaparib target in ovarian cancer with p.R346fs?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_031",
        "drug": "Olaparib",
        "gene": "MBD4",
        "mutation": "p.R346fs",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "MBD4+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "BER"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "MBD4": 0.1174664233026257
          },
          "clinical_evidence": {
            "pmid": "30111527",
            "evidence_level": "Preclinical"
          }
        },
        "mutations": [
          {
            "gene": "MBD4",
            "hgvs_p": "p.R346fs",
            "chrom": "3",
            "pos": 129430488,
            "ref": "?",
            "alt": "?",
            "consequence": "frameshift_variant"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "MBD4": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_032",
      "question": "What mechanisms does Ceralasertib target in breast cancer with p.R175H?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_032",
        "drug": "Ceralasertib",
        "gene": "TP53",
        "mutation": "p.R175H",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "TP53+ATR"
          ],
          "effective_drugs": [
            "Ceralasertib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "ATR/CHK1"
          ],
          "depmap_essentiality": {
            "TP53": 0.0
          },
          "clinical_evidence": {
            "pmid": "33115855",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "TP53",
            "hgvs_p": "p.R175H",
            "chrom": "17",
            "pos": 7577120,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "TP53": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_033",
      "question": "What mechanisms does Adavosertib target in prostate cancer with p.R175H?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_033",
        "drug": "Adavosertib",
        "gene": "TP53",
        "mutation": "p.R175H",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "TP53+WEE1"
          ],
          "effective_drugs": [
            "Adavosertib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "ATR/CHK1"
          ],
          "depmap_essentiality": {
            "TP53": 0.0
          },
          "clinical_evidence": {
            "pmid": "32592347",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "TP53",
            "hgvs_p": "p.R175H",
            "chrom": "17",
            "pos": 7577120,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "TP53": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_034",
      "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_034",
        "drug": "Olaparib",
        "gene": "ATM",
        "mutation": "p.?",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "ATM+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "ATM": 0.028631024194835045
          },
          "clinical_evidence": {
            "pmid": "29880560",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "ATM",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "ATM": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_035",
      "question": "What mechanisms does Olaparib target in breast cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_035",
        "drug": "Olaparib",
        "gene": "PALB2",
        "mutation": "p.?",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "PALB2+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "PALB2": 0.3409024137324467
          },
          "clinical_evidence": {
            "pmid": "32592347",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "PALB2",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "PALB2": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_036",
      "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_036",
        "drug": "Olaparib",
        "gene": "RAD51C",
        "mutation": "p.?",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "RAD51C+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "RAD51C": 0.6334293589307343
          },
          "clinical_evidence": {
            "pmid": "30345854",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "RAD51C",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "RAD51C": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_037",
      "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_037",
        "drug": "Olaparib",
        "gene": "RAD51D",
        "mutation": "p.?",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "RAD51D+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "RAD51D": 0.7360546282435787
          },
          "clinical_evidence": {
            "pmid": "30345854",
            "evidence_level": "Phase2"
          }
        },
        "mutations": [
          {
            "gene": "RAD51D",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "RAD51D": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_038",
      "question": "What mechanisms does Ceralasertib target in breast cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_038",
        "drug": "Ceralasertib",
        "gene": "ARID1A",
        "mutation": "p.?",
        "disease": "breast cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "ARID1A+ATR"
          ],
          "effective_drugs": [
            "Ceralasertib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "ATR/CHK1"
          ],
          "depmap_essentiality": {
            "ARID1A": 0.2762992755625062
          },
          "clinical_evidence": {
            "pmid": "30510156",
            "evidence_level": "Preclinical"
          }
        },
        "mutations": [
          {
            "gene": "ARID1A",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "breast_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "ARID1A": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_039",
      "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_039",
        "drug": "Olaparib",
        "gene": "CDK12",
        "mutation": "p.?",
        "disease": "prostate cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "CDK12+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "G1/S Checkpoint"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "CDK12": 0.42475616619423795
          },
          "clinical_evidence": {
            "pmid": "31320749",
            "evidence_level": "Preclinical"
          }
        },
        "mutations": [
          {
            "gene": "CDK12",
            "hgvs_p": "p.?",
            "chrom": "?",
            "pos": 0,
            "ref": "?",
            "alt": "?",
            "consequence": "unknown"
          }
        ]
      },
      "context": {
        "disease": "prostate_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "CDK12": "MUTATED"
        }
      }
    },
    {
      "query_id": "SL_040",
      "question": "What mechanisms does Olaparib target in ovarian cancer with p.C61G?",
      "source": "synthetic_lethality",
      "source_data": {
        "case_id": "SL_040",
        "drug": "Olaparib",
        "gene": "BRCA1",
        "mutation": "p.C61G",
        "disease": "ovarian cancer",
        "ground_truth": {
          "synthetic_lethality_detected": true,
          "known_sl_pairs": [
            "BRCA1+PARP1"
          ],
          "effective_drugs": [
            "Olaparib",
            "Niraparib"
          ],
          "broken_pathways": [
            "HR"
          ],
          "essential_pathways": [
            "PARP"
          ],
          "depmap_essentiality": {
            "BRCA1": 0.44405918068595746
          },
          "clinical_evidence": {
            "pmid": "25366685",
            "evidence_level": "FDA"
          }
        },
        "mutations": [
          {
            "gene": "BRCA1",
            "hgvs_p": "p.C61G",
            "chrom": "17",
            "pos": 43070943,
            "ref": "?",
            "alt": "?",
            "consequence": "missense"
          }
        ]
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {
          "BRCA1": "MUTATED"
        }
      }
    },
    {
      "query_id": "HV_001",
      "question": "How does Vitamin D help with ovarian cancer?",
      "source": "hypothesis_validator",
      "source_data": {
        "food": "Vitamin D",
        "cancer": "ovarian cancer",
        "targets": [
          "VDR",
          "TP53 pathway",
          "DNA repair",
          "Immune function",
          "BRCA1"
        ],
        "pathways": []
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {}
      }
    },
    {
      "query_id": "HV_002",
      "question": "How does Omega-3 Fatty Acids (EPA/DHA) help with ovarian cancer?",
      "source": "hypothesis_validator",
      "source_data": {
        "food": "Omega-3 Fatty Acids (EPA/DHA)",
        "cancer": "ovarian cancer",
        "targets": [
          "NF-\u03baB",
          "COX-2",
          "IL-6",
          "Membrane integrity",
          "Prostaglandins"
        ],
        "pathways": []
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {}
      }
    },
    {
      "query_id": "HV_003",
      "question": "How does Folate + Vitamin B12 help with ovarian cancer?",
      "source": "hypothesis_validator",
      "source_data": {
        "food": "Folate + Vitamin B12",
        "cancer": "ovarian cancer",
        "targets": [
          "DNA synthesis",
          "DNA repair",
          "Methylation",
          "One-carbon metabolism",
          "Homocysteine metabolism"
        ],
        "pathways": []
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {}
      }
    },
    {
      "query_id": "HV_004",
      "question": "How does Curcumin (Turmeric) help with ovarian cancer?",
      "source": "hypothesis_validator",
      "source_data": {
        "food": "Curcumin (Turmeric)",
        "cancer": "ovarian cancer",
        "targets": [
          "NF-\u03baB",
          "COX-2",
          "STAT3",
          "Apoptosis",
          "HSP90"
        ],
        "pathways": []
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {}
      }
    },
    {
      "query_id": "HV_005",
      "question": "How does Green Tea (EGCG) help with ovarian cancer?",
      "source": "hypothesis_validator",
      "source_data": {
        "food": "Green Tea (EGCG)",
        "cancer": "ovarian cancer",
        "targets": [
          "Proteasome",
          "Autophagy",
          "STAT3",
          "VEGF",
          "HSP90"
        ],
        "pathways": []
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {}
      }
    },
    {
      "query_id": "HV_006",
      "question": "How does NAC (N-Acetylcysteine) help with ovarian cancer?",
      "source": "hypothesis_validator",
      "source_data": {
        "food": "NAC (N-Acetylcysteine)",
        "cancer": "ovarian cancer",
        "targets": [
          "Glutathione",
          "Oxidative stress",
          "Mitochondria",
          "ROS buffering"
        ],
        "pathways": []
      },
      "context": {
        "disease": "ovarian_cancer",
        "treatment_line": "L1",
        "biomarkers": {}
      }
    }
  ]
}